Mesoblast Ltd MSB-AU:ASX

*Data is delayed | Exchange | AUD
Last | 04/24/24 AET
0.915quote price arrow up+0.015 (+1.67%)
Volume
7,616,298
52 week range
0.25 - 1.35
Loading...
  • Open0.92
  • Day High0.935
  • Day Low0.89
  • Prev Close0.90
  • 52 Week High1.35
  • 52 Week High Date07/17/23
  • 52 Week Low0.25
  • 52 Week Low Date02/08/24

Key Stats

  • Market Cap497.96M
  • Shares Out1,014.8M
  • 10 Day Average Volume8.5M
  • Dividend-
  • Dividend Yield-
  • Beta2.63
  • YTD % Change195.16

KEY STATS

  • Open0.92
  • Day High0.935
  • Day Low0.89
  • Prev Close0.90
  • 52 Week High1.35
  • 52 Week High Date07/17/23
  • 52 Week Low0.25
  • 52 Week Low Date02/08/24
  • Market Cap497.96M
  • Shares Out1,014.8M
  • 10 Day Average Volume8.5M
  • Dividend-
  • Dividend Yield-
  • Beta2.63
  • YTD % Change195.16

RATIOS/PROFITABILITY

  • EPS (TTM)-0.14
  • P/E (TTM)-6.65
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Mesoblast Ltd

 

Profile

MORE
Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic...
William Burns
Non-Executive Independent Vice Chairman of the Board
Jane Bell
Non-Executive Independent Chairman of the Board
Silviu Itescu
Chief Executive Officer, Executive Director
Dagmar Rosa-Bjorkeson
Chief Operating Officer
Andrew Chaponnel
Interim Chief Financial Officer
Peter Howard
General Counsel, Corporate Executive
Address
L 38 55 Collins St
Melbourne, VIC
3000
Australia